首页> 美国卫生研究院文献>Clinical and Applied Thrombosis/Hemostasis >Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study
【2h】

Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study

机译:在电子健康记录中实施突发期应用中的抗凝管理的管理:一项潜在的队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Appropriate perioperative management of patients on chronic oral anticoagulation (OAC)—including warfarin and the direct oral anticoagulants—is a poorly defined yet important clinical issue with potentially severe consequences in the postoperative period. We sought to prospectively evaluate the effect of the Management of Anticoagulation in the Periprocedural Period (MAPPP) mobile app as a clinical decision tool in the management of patients on chronic OAC undergoing elective procedures or surgeries. Between January 1, 2018, and January 31, 2019, 642 patients treated in our health system were included. Eligible patients met the following criteria: age >18 years old, creatinine clearance ≥15 mL/min, and on chronic OAC with adequate information regarding baseline characteristics. Our study outcome was patient’s emergency department (ED) visits within 30 days postprocedure. The MAPPP app was integrated into the electronic health record (EHR), and the end user was free to accept or decline recommended evidence-based perioperative anticoagulation management guidance. Analysis revealed that acceptance was more common in younger patients (P = .0137), patients on oral anticoagulants other than warfarin (P < .0001), and patients undergoing increased bleeding risk procedures (P = .0068). Acceptance of the MAPPP app recommendation was significantly associated with fewer ED visits (acceptance group: 4.0% vs rejection group: 8.3%, P = .0205). Logistic regression showed that intervention acceptance and female gender were significantly associated with fewer—while age ≥80 with more—30-day ED visits. Our findings indicate that newer technologies, such as the MAPPP app, integrated into clinical EHR workflow, can significantly augment evidence-based perioperative anticoagulation management and potentially result in a reduction of adverse outcomes.
机译:慢性口服抗凝患者(OAC)患者的适当围手术期诊断 - 华法林和直接口服抗凝血剂 - 是术后时期潜在严重后果的一个差异差异尚未定义的临床问题。我们试图潜在评估抗凝治疗在跨社会期(MAPPP)移动应用程序中抗凝治疗的影响,作为慢性OAC患者进行选修程序或手术的患者的临床决策工具。 2018年1月1日至2019年1月31日之间,包括在我们的卫生系统中治疗的642名患者。符合条件的患者符合以下标准:年龄> 18岁,肌酐清除≥15毫升/分钟,并以足够的基线特征提供足够的信息。我们的研究结果是患者的急诊部门(ED)在后期后30天内访问。 MAPPP应用程序已集成到电子健康记录(EHR)中,最终用户可以自由接受或下降推荐的基于证据的围攻抗凝管理指导。分析显示,在较年轻的患者(P = .0137)中,患者的患者患者更常见,患者在华法林(P <.0001)以外的口服抗凝血剂和患者上进行出血风险程序(P = .0068)。接受MAPPP应用程序推荐与较少的申请(验收组:4.0%VS拒绝组:8.3%,P = .0205)显着相关。 Logistic回归显示,干预验收和女性性别与较少的≥80较少相关,较多的次数达到次数。我们的研究结果表明,较新技术,如MAPPP应用程序,集成到临床EHR工作流程中,可以显着增加基于证据的围手术期抗凝管理,并且可能导致减少不利结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号